Relay Therapeutics (RLAY) CEO gets 1.45M option award grant details

Rhea-AI Filing Summary

Relay Therapeutics, Inc. reported that President and CEO Sanjiv Patel received a stock option grant. On January 13, 2026, he was awarded an option to buy 1,450,000 shares of Relay Therapeutics common stock at an exercise price of $7.94 per share. The filing states that the shares underlying this option will vest in sixteen equal quarterly installments after January 13, 2026, so long as he continues to serve with the company through each vesting date. Following this grant, he beneficially owned 1,450,000 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Sanjiv

(Last) (First) (Middle)

C/O RELAY THERAPEUTICS, INC.

60 HAMPSHIRE STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.94	01/13/2026		A		1,450,000		(1)	01/12/2036	Common Stock	1,450,000	$0.00	1,450,000	D

Explanation of Responses:

1. The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 13, 2026, subject to the reporting person's continued service with the Issuer through each vesting date.

	/s/ Soo-Yeun Lim, as Attorney-in-Fact	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Relay Therapeutics (RLAY) report for its CEO?

The company reported that President and CEO Sanjiv Patel received a grant of stock options on January 13, 2026, giving him the right to buy Relay Therapeutics common stock.

How many stock options did Relay Therapeutics (RLAY) grant to CEO Sanjiv Patel?

Relay Therapeutics granted 1,450,000 stock options to CEO Sanjiv Patel, as disclosed in the derivative securities table.

What is the exercise price of the new stock options granted to the Relay Therapeutics CEO?

The stock option granted to the CEO has an exercise price of $7.94 per share for Relay Therapeutics common stock.

How do the CEO’s Relay Therapeutics stock options vest?

The options underlying 1,450,000 shares will vest in sixteen equal quarterly installments after January 13, 2026, subject to his continued service with the company on each vesting date.

How many Relay Therapeutics derivative securities does the CEO own after this grant?

After the reported transaction, CEO Sanjiv Patel beneficially owned 1,450,000 derivative securities, held directly.

Is the stock option grant to the Relay Therapeutics CEO reported as direct or indirect ownership?

The filing shows the CEO’s ownership of the 1,450,000 stock options as direct ownership.